Correlation between the type of bcr-abl transcripts and blood cell counts in chronic myeloid leukemia - a possible influence of mdr1 gene expression

Hematology Reviews

Volumn 3, Issue 1, 2011, Pages 5-9

  Balatzenko, Gueorgui ^a   Vundinti, Babu Rao ^b   Margarita, Guenova ^a  

^a National Specialized Hospital for Active Treatment of Hematological Diseases   (Bulgaria)

^b KEM HOSPITAL   (India)

Author keywords

B2a2; B3a2; Bcr abl breakpoint; Chronic myeloid leukemia; Mdr1 gene expression

Indexed keywords

MESSENGER RNA; BCR ABL PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1;

ADULT; AGE DISTRIBUTION; ARTICLE; BCR ABL GENE; BLOOD CELL COUNT; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HEMATOLOGICAL PARAMETERS; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MDR1 GENE; ONCOGENE; THROMBOCYTE COUNT; GENE; GENE EXPRESSION PROFILING; GENE FUNCTION; GENETIC CORRELATION; GENETIC VARIABILITY; HUMAN CELL;

EID: 79955440242     PISSN: 19706804     EISSN: 19706790     Source Type: Journal    
DOI: 10.4081/hr.2011.e3     Document Type: Article

References (38)

1. Quintás-Cardama A, Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 2009;113:1619-1630.
2. de Lemos JA, de Oliveira CM, Scerni AC, et al. Differential molecular response of the transcripts B2A2 and B3A2 to imatinib mesylate in chronic myeloid leukemia. Genet Mol Res 2005;4:803-811.
3. Lucas CM, Harris RJ, Giannoudis A, et al. Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript. Haematologica 2009;94:1362-1367.
4. Sharma P, Kumar L, Mohanty S, Kochupillai V. Response to Imatinib mesy-late in chronic myeloid leukemia patients with variant BCR-ABL fusion transcripts. Ann Hematol. 2010;89:241-247.
5. Mondal BC, Bandyopadhyay A, Majumdar S, et al. Molecular profiling of chronic myeloid leukemia in eastern India. Am J Hematol 2006;81:845-849.
6. Adler R, Viehmann S, Kuhlisch E, et al. Correlation of BCR/ABL transcript variants with patients' characteristics in childhood chronic myeloid leukaemia. Eur J Haematol 2009;82:112-118.
7. Inokuchi K, Inoue T, Tojo A, et al. A possible correlation between the type of bcr-abl hybrid messenger RNA and platelet count in Philadelphia-positive chronic myelogenous leukemia. Blood 1991;78:3125-3127.
8. Perego RA, Costantini M, Cornacchini G, et al. The possible influences of B2A2 and B3A2 BCR/ABL protein structure on throm-bopoiesis in chronic myeloid leukaemia. Eur J Cancer 2000;36:1395-1401.
9. Verschraegen CF, Kantarjian HM, Hirsch-Ginsberg C, et al. The breakpoint cluster region site in patients with Philadelphia chromosome-positive chronic myeloge-nous leukemia. Clinical, laboratory, and prognostic correlations. Cancer 1995;76: 992-997.
10. Rozman C, Urbano-Ispizua A, Cervantes F, et al. Analysis of the clinical relevance of the breakpoint location within M-BCR and the type of chimeric mRNA in chronic myelogenous leukemia. Leukemia 1995;9: 1104-1107.
11. Opalka B, Wandl UB, Kloke O, et al. No correlation between site of breakpoint in the BCR gene and platelet counts in Philadelphia chromosome-positive CML. Leuk Res 1992;16:937-939.
12. Melo J. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 1996;88:2375-2384.
13. Shepherd P, Suffolk R, Halsey J, Allan N. Analysis of molecular breakpoint and m-RNA transcripts in a prospective randomized trial of interferon in chronic myeloid leukaemia: no correlation with clinical features, cytogenetic response, duration of chronic phase, or survival. Br J Haematol 1995;89:546-554.
14. Giles FJ, Kantarjian HM, Cortes J, et al. Multidrug resistance protein expression in chronic myeloid leukemia: associations and significance. Cancer 1999;86:805-813.
15. Leonard GD, Fojo T, Bates SE. The role of ABC transporters in clinical practice. Oncologist 2003;8:411-424.
16. Nüssler V, Pelka-Fleischer R, Zwierzina H, et al. Clinical importance of P-glycoprotein related resistance in leukemia and myelodysplastic syndromes first experience with their reversal. Ann Hematol 1994;69:S25-S29.
17. Sato H, Gottesman MM, Goldstein LJ, et al. Expression of the multi drug resistance gene in myeloid leukemias. Leuk Res 1990;14:11-21.
18. Stavrovskaya A, Turkina A, Sedyakhina N, et al. Prognostic value of P-glycoprotein and leukocyte differentiation antigens in chronic myeloid leukemia. Leuk Lymphoma 1998;28:469-482.
19. Michelutti A, Michieli M, Damiani D, et al. Overexpression of MDR-related p170 glycoprotein in chronic myeloid leukemia. Haematologica 1994;79:200-204.
20. Herweijer H, Sonneveld P, Baas F, Nooter K. Expression of mdr1 and mdr3 multi drug resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporine. J Natl Cancer Inst 1990;82:1133-1340.
21. Isotalo PA, Wells GA, Donnelly JG. Neonatal and fetal methylenetetrahydrofolate reductase genetic polymorphisms: an examination of C677T and A1298C mutations. Am J Hum Genet 2000;67:986-990.
22. van Dongen JJ, Macintyre EA, Gabert JA, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia. 1999;13:1901-1928.
23. Veelken H, Licht T, Lais A, et al. Drug resistance of secondary acute myeloid leukemia with megakaryoblastic features and p190 BCR-ABL rearrangement. Leuk Res 1998;22:1021-1027.
24. Kwok S, Higuchi R. Avoiding false positives with PCR. Nature 1989; 18;339:237-238.
25. Cambier N, Chopra R, Strasser A, et al. BCR-ABL activates pathways mediating cytokine independence and protection against apoptosis in murine hematopoietic cells in a dose-dependent manner. Oncogene 1998;16:335-348.
26. Weide R, Dowding C, Paulsen W, Goldman J. The role of the MDR-1/P-170 mechanism in the development of multidrug resistance in chronic myeloid leukemia. Leukemia 1990;4:695-699.
27. Leith C P, Kopecky K J, Chen IM, et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood 1999;94:1086-1099.
28. Damiani D, Michelutti A, Michieli M, et al. P-glycoprotein, lung resistance-related protein and multidrug resistance-associated protein in de novo adult acute lymphoblastic leukaemia. Br J Haematol 2002;116:519-27.
29. Svoboda-Beusan I, Kusec R, Bendelja K, et al. The relevance of multidrug resistance-associated P-glycoprotein expression in the treatment response of B-cell chronic lymphocytic leukemia. Haematologica 2000;85:1261-1267.
30. Schaich M, Illmer T. Mdr1 gene expression and mutations in Ras proto-oncogenes in acute myeloid leukemia. Leuk Lymphoma. 2002;43:1345-1354.
31. Sukhai M, Piquette-Miller M. Regulation of the multi drug resistance genes by stress signals. J Pharm Pharm Sci 2000;3:268-280.
32. Raitano AB, Halpern JR, Hambuch TM, Sawyers CL. The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. Proc Natl Acad Sci USA 1995;92:11746-11750.
33. Fan E, Hu Y, Zhao C. Human stem cell model to study signal transduction and molecular regulation mechanisms in CML. Chin Med J (Engl) 2001;114:680-684.
34. Garcia-Manero G, Daniel J, Smith TL, et al. DNA methylation of multiple promoter associated CpG islands in adult acute lym-phocytic leukemia. Clin Cancer Res 2002;8:2217-24.
35. Takane Takane H, Kobayashi D, Hirota T, et al. Haplotype-oriented genetic analysis and functional assessment of promoter variants in the MDR1 (ABCB1) gene. J Pharmacol Exp Ther 2004;311:1179-1187.
36. Illmer T, Schuler US, Thiede C, et al. MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res 2002;62:4955-4962.
37. Taheri M, Mahjoubi F, Omranipour R. Effect of MDR1 polymorphism on multi drug resistance expression in breast cancer patients. Genet Mol Res 2010;9:34-40.
38. Illmer T, Schaich M, Platzbecker U, et al. P glycoprotein mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia 2004;18:401-408.